Ayesha Appa is an Infectious Disease physician affiliated with San Francisco General Hospital. OpenAlex indexes 58 publications with 825 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1001 Potrero Ave
San Francisco, CA 941103518
Telephone
628-206-8000Provider last certified this registry record 2 Apr 2026.
Clinical trials
- Naltrexone for Overdose Prevention
Sponsor: University of California, San Francisco
- Contingency Management in HIV Care for Both Stimulant Use & ART Adherence
Sponsor: University of California, San Francisco
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
23.7%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor12.3%Triumeq100%Part D<11 patientsProtease Inhibitor5.7%Prezcobix100%Part D<11 patients+ 1 more class in this area
Nervous system
23.7%Gabapentinoids8.1%Gabapentin100%Part D<11 patientsSNRI5.2%Venlafaxine Hcl Er100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
20.9%Statin15.6%Atorvastatin Calcium100%Part D<11 patientsACE inhibitor5.2%Benazepril Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2024 per NIH RePORTER. The latest:
- Taking Our Shot: Extended-Release Naltrexone as Opioid Overdose Pre-Exposure Prophylaxis (PrEP) in People Using Stimulants Living With or At Risk of HIV
University of California, San Francisco
FY2024$2,460,000DP2DA060600
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Deeks, MD
San Francisco General Hospital
Geoffrey Manley, MD, PhD
San Francisco General Hospital
Francesca Delling, MD
San Francisco General Hospital
Melvin Cheitlin, MD
San Francisco General Hospital
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”